drugset / Trial / NCT04085341
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema and Retinal Vein Occlusion
Timeline
- Start
- 2019-09-11
- Primary completion
- 2020-06-05
- Completion
- 2020-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 1 mg | Intravitreal |
| Subject | Sunitinib | Small molecule | 2 mg | Intravitreal |